Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 40%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC demonstrated robust growth in 2025, with KIMMTRAK generating $400 million in sales, reflecting a 29% year-over-year increase, driven by high penetration rates of over 70% across various geographies and an extended duration of therapy averaging around 14 months. The company is currently focusing on expanding KIMMTRAK's application to cutaneous melanoma, which, if successful, could significantly enhance its commercial prospects, with peak potential annual revenues in this area estimated at $500 million, contingent on positive clinical outcomes. Overall, Immunocore’s strong financial trajectory, driven by solid sales performance and strategic pipeline expansions, supports a positive outlook on the company’s stock.

Bears say

Immunocore Holdings PLC faces a negative outlook due to the potential lack of observed clinical benefits in future PRAME clinical readouts, which is expected to result in a significant downside to current projections. The company may struggle to generate additional successful clinical candidates beyond its current platforms, raising concerns about its ability to diversify its product portfolio. Additionally, treatment-emergent adverse events from ongoing trials imply potential safety concerns, while the consistent treatment landscape indicates a persistent unmet medical need that may limit market potential for its therapies.

Immunocore Holdings (IMCR) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 40% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 10 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.